Your browser is no longer supported. Please, upgrade your browser.
SGEN Seattle Genetics, Inc. daily Stock Chart
SGEN [NASD]
Seattle Genetics, Inc.
Index- P/E- EPS (ttm)-0.97 Insider Own0.90% Shs Outstand175.66M Perf Week6.63%
Market Cap20.47B Forward P/E- EPS next Y-1.40 Insider Trans-13.77% Shs Float170.95M Perf Month-1.94%
Income-158.70M PEG- EPS next Q-0.78 Inst Own- Short Float2.88% Perf Quarter3.43%
Sales916.70M P/S22.33 EPS this Y32.10% Inst Trans0.00% Short Ratio4.17 Perf Half Y37.07%
Book/sh10.93 P/B10.66 EPS next Y51.70% ROA-8.50% Target Price126.19 Perf Year57.89%
Cash/sh4.62 P/C25.23 EPS next 5Y23.00% ROE-10.20% 52W Range62.90 - 124.32 Perf YTD1.97%
Dividend- P/FCF- EPS past 5Y-9.20% ROI-11.80% 52W High-6.28% Beta1.40
Dividend %- Quick Ratio4.20 Sales past 5Y26.20% Gross Margin95.20% 52W Low85.23% ATR7.94
Employees1605 Current Ratio4.50 Sales Q/Q66.10% Oper. Margin-24.10% RSI (14)56.23 Volatility4.98% 8.07%
OptionableYes Debt/Eq0.00 EPS Q/Q120.10% Profit Margin-17.30% Rel Volume0.64 Prev Close118.67
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume1.18M Price116.51
Recom2.30 SMA2010.02% SMA504.86% SMA20021.78% Volume753,198 Change-1.82%
Feb-18-20Downgrade Barclays Overweight → Equal Weight $124
Feb-12-20Reiterated H.C. Wainwright Buy $140 → $150
Feb-11-20Reiterated Goldman Buy $126 → $165
Jan-28-20Initiated BMO Capital Markets Outperform
Jan-27-20Initiated BMO Capital Markets Outperform
Jan-02-20Downgrade Guggenheim Buy → Neutral
Dec-10-19Initiated Morgan Stanley Equal-Weight
Dec-03-19Resumed BofA/Merrill Neutral
Oct-22-19Reiterated H.C. Wainwright Buy $98 → $140
Oct-22-19Reiterated BofA/Merrill Underperform $58 → $83
Sep-27-19Upgrade Goldman Neutral → Buy $78 → $100
Aug-26-19Initiated BTIG Research Neutral
Jul-18-19Initiated Deutsche Bank Hold $79
Jul-17-19Upgrade Piper Jaffray Neutral → Overweight $64 → $75
Apr-11-19Initiated Stifel Hold $70
Mar-27-19Initiated Berenberg Buy $95
Oct-26-18Reiterated Barclays Overweight $95 → $90
Oct-26-18Downgrade BofA/Merrill Neutral → Underperform
Sep-25-18Initiated Leerink Partners Outperform
Sep-07-18Resumed Piper Jaffray Neutral
Apr-03-20 12:06PM  Seattle Genetics Issue Update on Padcev Label Expansion Study Zacks
Apr-02-20 04:44PM  Stock Indexes Jump As Jobless Claims Soar Again Investor's Business Daily +6.68%
04:37PM  Biotech Nears A Breakout As FDA Mulls Speedy Approval For Cancer Drug Investor's Business Daily
11:04AM  Seattle Genetics Nears Buy Point Investor's Business Daily Video
08:00AM  Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer Business Wire
Mar-17-20 05:54PM  Hedge Funds Have Never Been This Bullish On Seattle Genetics, Inc. (SGEN) Insider Monkey +5.20%
08:59AM  Is There An Opportunity With Seattle Genetics, Inc.'s (NASDAQ:SGEN) 46% Undervaluation? Simply Wall St.
Mar-10-20 08:00AM  Seattle Genetics to Webcast Virtual Fireside Chat at Barclays Global Healthcare Conference Business Wire
Mar-07-20 11:30AM  Why Is Seattle Genetics (SGEN) Down 3.2% Since Last Earnings Report? Zacks
Mar-02-20 08:00AM  Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference Business Wire
Feb-26-20 08:00AM  Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference Business Wire
Feb-19-20 05:12PM  Seattle Genetics bladder drug gets breakthrough therapy designation American City Business Journals
09:21AM  Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates Zacks
08:28AM  Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer PR Newswire
08:12AM  Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer Business Wire
Feb-13-20 08:00AM  Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Feb-12-20 09:18AM  The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga
Feb-11-20 08:00AM  Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer Business Wire
Feb-10-20 07:01PM  Edited Transcript of SGEN earnings conference call or presentation 6-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
05:00PM  Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer PR Newswire
10:51AM  Seattle Genetics, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
09:37AM  3 Nasdaq 100 Stocks With Excellent Upside Potential Investopedia
Feb-07-20 11:15AM  Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales Zacks
Feb-06-20 05:25PM  Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates Zacks
05:07PM  Biotech Giant Crushes Sales Estimates And Posts A Profit But Shares Dive Investor's Business Daily
04:02PM  Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
02:30PM  Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
Feb-05-20 09:45AM  Why Seattle Genetics (SGEN) Might Surprise This Earnings Season Zacks +6.09%
Jan-31-20 08:00AM  EMA Validates Seattle Genetics Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Jan-30-20 12:31PM  Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jan-21-20 06:13PM  Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe Zacks
08:30AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020 Business Wire
08:00AM  Seattle Genetics Achieves Milestone Following European Commission Approval of Roches Polivy® (Polatuzumab Vedotin) Business Wire
Jan-20-20 09:32AM  Seattle Genetics Up More Than 40% in the Past Year: Here's Why Zacks
Jan-16-20 08:56AM  How Much is Seattle Genetics, Inc.'s (NASDAQ:SGEN) CEO Getting Paid? Simply Wall St.
Jan-09-20 04:24PM  How Did Seattle Genetics, Inc. (SGEN) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Jan-06-20 08:00AM  Seattle Genetics to Present at the J.P. Morgan Healthcare Conference Business Wire
Dec-30-19 10:09AM  Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline Zacks
Dec-26-19 08:13PM  What could you have made by investing $1,000 in these Washington companies a decade ago? American City Business Journals
02:47PM  Tech will drive change in health care throughout next decade American City Business Journals
Dec-24-19 01:12PM  Seattle Genetics Submits NDA to FDA for Tucatinib Combo Zacks
Dec-23-19 08:00AM  Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Dec-19-19 03:17PM  Seattle Genetics gets accelerated approval for cancer-killing drug American City Business Journals
12:02PM  Seattle Genetics' stock rises on approval of bladder cancer drug MarketWatch
11:35AM  Seattle Genetics Gets Speedy FDA Nod for Bladder Cancer Drug Zacks
10:37AM  Why This Leading Biotech Stock Just Added To Its 99% Gain This Year Investor's Business Daily
09:07AM  Seattle Genetics Drug For Difficult-To-Treat Urothelial Cancer Gets Early FDA Nod Benzinga
07:52AM  The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
Dec-18-19 07:49PM  FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer PR Newswire
06:42PM  Seattle Genetics to Host Conference Call and Webcast on December 19, 2019 to Discuss PADCEVTM (enfortumab vedotin-ejfv) Approval Business Wire
06:36PM  FDA Grants Accelerated Approval to Astellas and Seattle Genetics PADCEV (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer Business Wire
08:00AM  Seattle Genetics Announces U.S. FDA Grants Breakthrough Therapy Designation for Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Dec-12-19 04:57PM  Seattle Genetics' Cancer Study Boosts Prospects, Takeover Appeal GuruFocus.com
Dec-11-19 10:31AM  When Will Seattle Genetics, Inc. (NASDAQ:SGEN) Turn A Profit? Simply Wall St.
09:54AM  Seattle Genetics Announces Positive Tucatinib HER2CLIMB Trial Results in Locally Advanced or Metastatic HER2-Positive Breast Cancer Presented at 2019 SABCS and Published in the New England Journal of Medicine Business Wire
Dec-09-19 10:00AM  Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting Business Wire
Dec-07-19 02:00PM  Seattle Genetics Announces Updated Data of ADCETRIS® (Brentuximab Vedotin) in Combination with OPDIVO® (Nivolumab) in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting Business Wire
08:35AM  The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-06-19 11:49AM  Hedge Funds Had Impeccable Timing Buying Seattle Genetics, Inc. (SGEN) Insider Monkey
Dec-04-19 10:02AM  Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks
Dec-03-19 10:45AM  Seattle Genetics, Astellas Tie Up With Merck for Cancer Study Zacks
09:26AM  Where to Buy Booming Biotech ETFs Investopedia
Dec-02-19 09:21PM  This is what workers earn at some of Washington's largest public companies American City Business Journals
08:00AM  Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer Business Wire
Nov-28-19 09:31AM  Seattle Genetics (SGEN) Up 15.7% Since Last Earnings Report: Can It Continue? Zacks
Nov-26-19 08:06AM  The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug Benzinga
Nov-25-19 08:00AM  Seattle Genetics Announces Health Canada Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy in Frontline CD30-Expressing Peripheral T-Cell Lymphoma Business Wire
Nov-21-19 09:56AM  The Medicines Company Soars Amid Acquisition Whispers Investopedia
Nov-13-19 07:10AM  The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher Benzinga
Nov-12-19 05:15PM  Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership Business Wire
Nov-07-19 08:00AM  Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the ASH Annual Meeting Business Wire
Nov-05-19 08:00AM  Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate Business Wire
06:53AM  The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga
Nov-04-19 11:51PM  Seattle Genetics Responds to Daiichi Sankyos Complaint for Declaratory Judgment Business Wire
08:00AM  Seattle Genetics to Present at Credit Suisse 28th Annual Healthcare Conference Business Wire
Nov-01-19 10:03AM  Baker Brothers Make $1.4 Billion in Two Weeks on Biotech Bloomberg
07:36AM  Edited Transcript of SGEN earnings conference call or presentation 29-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-30-19 12:29PM  Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark Zacks
Oct-29-19 05:25PM  Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:02PM  Seattle Genetics Reports Third Quarter 2019 Financial Results Business Wire
Oct-27-19 12:56PM  The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings Benzinga
Oct-23-19 09:45AM  Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates Zacks
Oct-22-19 10:06AM  Seattle Genetics: Where's This Biotech Stock Headed From Here? TheStreet.com
Oct-21-19 04:15PM  This Biotech Stock Piggybacked On Roche's Blockbuster And Succeeded Investor's Business Daily +15.43%
03:20PM  Seattle Genetics Options Volume Skyrockets as Shares Soar Schaeffer's Investment Research
12:59PM  Dow Jones Lags, Boeing Bombarded Again; These Growth Stocks Are Emerging As New Leaders Investor's Business Daily
12:42PM  Baker Brothers Makes $730 Million in One Day on Its Biotech Bet Bloomberg
10:01AM  Here's Why We're Not At All Concerned With Seattle Genetics's (NASDAQ:SGEN) Cash Burn Situation Simply Wall St.
09:58AM  Seattle Genetics stock soars 15% on positive trial of breast cancer treatment MarketWatch
09:36AM  Seattle Genetics Rallies To Record High On Positive Results From Midstage Breast Cancer Study Benzinga
07:04AM  Seattle Genetics Shares Rise On Positive Results From Breast Cancer Drug Trial TheStreet.com
06:45AM  Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Oct-16-19 03:23PM  Four stocks that are nearing key breakouts MarketWatch
11:51AM  4 Stocks Nearing Key Breakouts Benzinga
Oct-12-19 02:16PM  Did Hedge Funds Drop The Ball On Seattle Genetics, Inc. (SGEN) ? Insider Monkey
Oct-11-19 12:40PM  Seattle Genetics Begins Phase III Study on Tucatinib Combo Zacks
Oct-10-19 11:15AM  Seattle Genetics Up More Than 20% in 3 Months: Here's Why Zacks
08:00AM  Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Oct-08-19 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2019 Financial Results on October 29, 2019 Business Wire
Oct-06-19 07:55AM  Goldman Sachs: 3 Stocks to Buy Despite Recession Fears TipRanks
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seattle Genetics, Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and biotechnology and pharmaceutical companies. Seattle Genetics, Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIEGALL CLAY BPresident and CEOMar 09Option Exercise12.0028,472341,664768,581Mar 11 06:51 PM
SIEGALL CLAY BPresident and CEOMar 09Sale110.0928,4723,134,578758,784Mar 11 06:51 PM
HIMES VAUGHN BChief Technical OfficerMar 06Option Exercise13.518,000108,117193,172Mar 10 08:12 PM
HIMES VAUGHN BChief Technical OfficerMar 06Sale114.918,000919,292188,674Mar 10 08:12 PM
DANSEY ROGER DChief Medical OfficerFeb 18Sale116.3335040,716107,659Feb 20 05:33 PM
SIEGALL CLAY BPresident and CEOFeb 10Option Exercise12.0028,472341,664768,723Feb 12 05:38 PM
SIEGALL CLAY BPresident and CEOFeb 10Sale114.6128,4723,263,110758,784Feb 12 05:38 PM
DANSEY ROGER DChief Medical OfficerFeb 03Sale108.5172778,887108,009Feb 05 06:08 PM
SIEGALL CLAY BPresident and CEOJan 08Option Exercise12.0028,472341,664785,937Jan 10 07:08 PM
SIEGALL CLAY BPresident and CEOJan 08Sale111.3228,4723,169,433758,784Jan 10 07:08 PM
WELCH DANIEL GDirectorJan 07Option Exercise12.7617,500223,30090,263Jan 09 08:32 PM
DANSEY ROGER DChief Medical OfficerDec 16Sale114.072,000228,140101,146Dec 17 06:48 PM
SIEGALL CLAY BPresident and CEODec 09Option Exercise12.0028,472341,664773,011Dec 10 07:15 PM
SIEGALL CLAY BPresident and CEODec 09Sale114.5628,4723,261,641755,684Dec 10 07:15 PM
HIMES VAUGHN BChief Technical OfficerDec 06Option Exercise12.008,00096,000195,518Dec 10 07:14 PM
HIMES VAUGHN BChief Technical OfficerDec 06Sale117.168,000937,265187,518Dec 10 07:14 PM
DANSEY ROGER DChief Medical OfficerNov 25Option Exercise65.115,000325,550108,146Nov 27 05:32 PM
DANSEY ROGER DChief Medical OfficerNov 25Sale121.485,000607,388103,146Nov 27 05:32 PM
AKKARAJU SRINIVASDirectorNov 21Option Exercise19.0217,500332,85052,726Nov 22 06:35 PM
AKKARAJU SRINIVASDirectorNov 21Sale119.7817,5002,096,12040,168Nov 22 06:35 PM
LIPPMAN MARC EDirectorNov 18Option Exercise15.8935,000556,150148,813Nov 20 06:41 PM
DANSEY ROGER DChief Medical OfficerNov 18Option Exercise65.115,000325,550108,146Nov 20 06:45 PM
DANSEY ROGER DChief Medical OfficerNov 18Sale116.005,000580,000103,146Nov 20 06:45 PM
LIPPMAN MARC EDirectorNov 18Sale115.8035,0004,053,000131,313Nov 20 06:41 PM
SIEGALL CLAY BPresident and CEONov 08Option Exercise12.0028,472341,664776,483Nov 12 06:24 PM
SIEGALL CLAY BPresident and CEONov 08Sale107.6128,4723,063,816755,684Nov 12 06:24 PM
SIEGALL CLAY BPresident and CEOOct 08Option Exercise12.0028,472341,664770,104Oct 10 06:55 PM
SIEGALL CLAY BPresident and CEOOct 08Sale82.4728,4722,348,061755,684Oct 10 06:55 PM
GRYSKA DAVID WDirectorOct 01Option Exercise15.895,00079,45050,513Oct 03 07:38 PM
GRYSKA DAVID WDirectorOct 01Sale85.095,000425,45048,013Oct 03 07:38 PM
SIMPSON TODD EChief Financial OfficerSep 30Sale85.0015,0001,275,000157,567Oct 02 06:12 PM
LIU JEAN IGC/EVP, Leg AffairsSep 30Sale86.007,432639,15270,688Oct 02 06:10 PM
DANSEY ROGER DChief Medical OfficerSep 25Sale73.803,000221,415103,146Sep 27 06:12 PM
SIEGALL CLAY BPresident and CEOSep 09Option Exercise12.0028,472341,664774,374Sep 10 07:29 PM
SIEGALL CLAY BPresident and CEOSep 09Sale68.3328,4721,945,531755,684Sep 10 07:29 PM
SIEGALL CLAY BSee RemarksSep 03Sale70.809,693686,257755,684Sep 04 09:46 PM
DANSEY ROGER DSee RemarksSep 03Sale70.8092265,277106,146Sep 04 09:43 PM
SIMPSON TODD ESee RemarksSep 03Sale70.802,092148,112172,567Sep 04 09:42 PM
HIMES VAUGHN BSee RemarksSep 03Sale70.805,692402,990187,518Sep 04 09:45 PM
HIMES VAUGHN BSee RemarksAug 30Option Exercise12.008,00096,000201,210Sep 04 09:45 PM
HIMES VAUGHN BSee RemarksAug 30Sale72.868,000582,859193,210Sep 04 09:45 PM
LIU JEAN IGC/EVP, Leg AffairsAug 28Sale73.226,013440,24260,904Aug 30 04:35 PM
SIEGALL CLAY BPresident and CEOAug 28Sale73.2128,9512,119,636717,343Aug 30 04:35 PM
SIMPSON TODD EChief Financial OfficerAug 28Sale73.215,909432,624153,371Aug 30 04:36 PM
HIMES VAUGHN BChief Technical OfficerAug 28Sale73.216,836500,496175,197Aug 30 04:35 PM
SIMPSON TODD EChief Financial OfficerAug 20Sale80.0012,5001,000,000159,280Aug 22 05:49 PM
LIU JEAN IGC/EVP, Leg AffairsAug 20Sale80.003,716297,28066,917Aug 22 05:47 PM
SIEGALL CLAY BPresident and CEOAug 08Option Exercise12.1620,149245,012756,192Aug 09 05:06 PM
SIEGALL CLAY BPresident and CEOAug 08Sale76.5220,1491,541,827746,294Aug 09 05:06 PM
LIU JEAN IGC/EVP, Leg AffairsAug 06Sale75.003,716278,70070,633Aug 08 05:42 PM
GRYSKA DAVID WDirectorJul 17Option Exercise12.765,00063,80053,013Jul 19 06:20 PM
GRYSKA DAVID WDirectorJul 17Sale75.005,000375,00048,013Jul 19 06:20 PM
SIEGALL CLAY BPresident and CEOJul 08Option Exercise12.1620,148245,000761,011Jul 10 06:57 PM
SIEGALL CLAY BPresident and CEOJul 08Sale66.8920,1481,347,664746,294Jul 10 06:57 PM
HIMES VAUGHN BChief Technical OfficerJun 24Option Exercise42.514,704199,970182,033Jun 26 06:26 PM
DANSEY ROGER DChief Medical OfficerJun 17Sale68.605,416371,53877,593Jun 19 06:43 PM
SIEGALL CLAY BPresident and CEOJun 10Option Exercise12.1620,148245,000760,119Jun 12 05:51 PM
SIEGALL CLAY BPresident and CEOJun 10Sale69.0520,1481,391,175749,169Jun 12 05:51 PM
HIMES VAUGHN BChief Technical OfficerMay 31Option Exercise12.008,00096,000185,329Jun 04 06:28 PM
HIMES VAUGHN BChief Technical OfficerMay 31Sale65.948,000527,485177,329Jun 04 06:28 PM
SIEGALL CLAY BPresident and CEOMay 09Option Exercise12.164,82458,660752,063May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 09Sale67.434,824325,301749,169May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 08Option Exercise12.1615,324186,340762,600May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 08Sale68.2615,3241,046,066749,169May 10 04:39 PM
BAKER BROS. ADVISORS LPDirectorApr 29Option Exercise8.3820,000167,60045,839,686May 01 04:59 PM
SIEGALL CLAY BPresident and CEOApr 08Option Exercise12.1620,148245,000757,976Apr 10 04:39 PM
SIEGALL CLAY BPresident and CEOApr 08Sale79.2220,1481,596,100749,169Apr 10 04:39 PM